Darby John Patrick sold $1.1M of EHC

Darby John Patrick (EVP, Gen Counsel & Secretary) sold 8,906 shares of Encompass Health Corp (EHC) at $125.95 ($1.12M total) on 2026-08-10.

Original reporting
SEC EDGAR · Darby John Patrick
Published Aug 11, 2026, 6:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 6:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EHC
Neutral
medium confidence
Mentioned
$EHC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EHCNeutralLow
01

Why it matters

The newest disclosed fact is the Aug 10 open-market sale of 8,906 shares by the company’s EVP, Gen Counsel, and Secretary, with holdings after the sale of 75,041 shares.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article does not state motivations, tax needs, or whether other related transactions occurred; absence of a 10b5-1 plan does not automatically imply information advantage.

Relevance 6/10Novelty 3/10Timing: filed Aug 11 after Aug 10 sale

Background

This is an SEC Form 4 insider transaction disclosure for Encompass Health Corp (EHC).

Company-level read

Ticker impact

$EHCNeutralMedium confidence
Context

Encompass Health Corp disclosed an insider open-market sale by EVP and Gen Counsel Darby John Patrick for 8,906 shares at $125.95.

Expected impact

Likely minimal near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

Form 4 provides transaction details (size, price, post-sale holdings) but no new company guidance, contracts, or operational developments.

Market effects

No clear sector read-through from a single routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification and may not reflect bearish expectations, especially when the filing lacks any accompanying negative company news.

Key entities

  • Encompass Health Corp

    US-listed healthcare services company subject of the Form 4 insider sale disclosure.

  • Darby John Patrick

    EVP, General Counsel, and Secretary who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EHCMed

Raymond James raises Encompass Health stock price target on strong results

Raymond James raised its price target for Encompass Health (EHC) to $155 from $150, citing strong Q3 results and raised guidance. The company beat EBITDA expectations for the 16th straight quarter, driven by acuity and cost control. EHC shares are near their 52-week high, up 32% in six months. Analysts like UBS, KeyBanc, and Truist also raised their price targets, noting strong EBITDA performance and positive 2027 outlook.

$EHCMedAI 8/10

KeyBanc raises Encompass Health stock price target on strong earnings

KeyBanc raised its price target for Encompass Health (NYSE:EHC) to $150 from $147, citing strong Q3 results. Core EBITDA beat estimates by 10% with 23% YoY growth, driven by acuity improvements and expense management. The company reported $1.52B EBITDA over the last 12 months. Same-store volumes grew 3.0%, with expectations of further improvement. Management is optimistic about 2027 and RCD expansion. The stock has returned 32% over six months, trading near its 52-week high of $133.75.

$EHCHigh

Truist raises Encompass Health stock price target on strong results

Truist Securities raised its price target on Encompass Health (NYSE:EHC) to $156 from $150, citing strong Q3 results. The company reported adjusted EBITDA of $1.52B and a 32% stock return over six months. Encompass Health raised its guidance despite headwinds and is expanding capacity. The stock trades near its 52-week high of $133.75, with a financial health score of 3.35 out of 5.